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Abstract
Background: The aim of this study was to assess the results of curative surgery with and without radiotherapy in 
patients with T1-2N0-1 oral tongue squamous cell carcinoma (OSCC) and to evaluate survival and prognostic factors.
Methods: Retrospective analysis of 86 patients with T1-2N0-1 OSCC who received surgery between January 2000 and 
December 2006. Fourteen patients (16.3%) received postoperative radiotherapy (PORT). Patient characteristics, tumor 
characteristics, treatment modality, failure patterns, and survival rates were analyzed.
Results: The median follow-up was 45 months. The five-year overall survival (OS) and disease-free survival (DFS) rates 
were 80.8% and 80.2%, respectively. Higher tumor grade and invasion depth ≥ 0.5 cm were the significant prognostic 
factors affecting five-year OS and DFS (OS rate; 65% vs. 91%, p = 0.001 for grade; 66% vs. 92%, p = 0.01 for invasion 
depth: DFS rate; 69% vs. 88%, p = 0.005 for grade; 66% vs. 92%, p = 0.013 for invasion depth). In the risk group, there was 
no local failure in patients with postoperative radiotherapy.
Conclusions: In T1-2N0-1 OSCC, factors that affected prognosis after primary surgery were higher tumor grade and deep 
invasion depth over 0.5 cm. Postoperative radiotherapy should be considered in early oral tongue cancer patients with 
these high-risk pathologic features.
Background
T h e  o r a l  t o n g u e  i s  t h e  m o s t  c o m m o n  s u b s i t e  f o r
squamous cell carcinoma of the oral cavity, excluding the
lip [1]. In advanced cases, surgical resection followed by
radiotherapy (RT) with or without chemotherapy is per-
formed, and it seems to be beneficial. In early cases (T1-
2), surgery is often the preferred form of treatment [2].
However, the management of cervical lymph nodes (LN)
and the role of postoperative adjuvant treatment remain
uncertain.
Although surgery has emerged as the preferred initial
treatment approach for the majority of patients with
tumors of the oral cavity, adjuvant postoperative radia-
tion is commonly recommended to enhance the likeli-
hood of locoregional tumor control [3]. The results of
two randomized trials suggest that postoperative chemo-
radiation may be beneficial in improving local-regional
control and disease-free survival among patients selected
for specific high-risk features of head and neck cancer
[4,5]. As with other head and neck cancers, postoperative
radiation therapy (PORT) in oral tongue squamous cell
carcinoma (OSCC) is recommended for patients with
large primary tumors (T3, T4), close or positive surgical
margins, and evidence of perineural invasion (PNI), mul-
tiple positive nodes, or extracapsular extension (ECS).
Data were limited for high-risk features of recurrence and
PORT in early-stage OSCC. Furthermore, most series
reported a mixed patient population with oral cavity can-
cer [6,7].
Because of the extremely low salvage rate of recurred
oral tongue cancer [8], the proper extent and modality of
initial treatment is very important. This study retrospec-
tively reviewed patients with oral tongue cancer treated
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at the Yonsei University Health System in Seoul, Korea, to
investigate the pathologic prognostic factors in patients
with T1-2N0-1  OSCC in terms of disease-free survival
(DFS) and overall survival (OS), and to verify the role of
PORT in patients with a high risk of recurrence.
Methods
Between 2000 and 2006, 234 patients with oral tongue
cancer were treated at the Yonsei University Health Sys-
tem, Seoul, Korea. Among them, 90 (38.5%) were treated
surgically at stage T1-2N0-1. Of these, one patient pre-
sented with myoepithelial carcinoma, and one patient
with adenoid cystic carcinoma. One patient who received
neoadjuvant chemotherapy before surgery and one
patient who received chemotherapy for acute lympho-
blastic leukemia before the diagnosis of oral tongue can-
cer were eliminated from the analysis. Finally, the medical
records of 86 patients were retrospectively reviewed with
institutional review board (IRB, Severance Hospital, Yon-
sei University Health System) approval. Tumor staging
was based on the pathology findings, according to the
American Joint Committee on Cancer Staging System, 6th
edition. In addition, the following variables were
recorded: size and invasion depth of the primary tumor
(tumor thickness), grade of differentiation, status of
resection margins, lymphovascular invasion, and
perineural invasion. The grade of differentiation was also
divided into two groups: well-differentiated and moder-
ate-to-poorly differentiated. To determine the status of
resection margins, the closest were labeled as positive for
a margin invaded by cancer cells, negative for a safety
margin not less than 0.5 cm, and close for the safety mar-
gin less than 0.5 cm. The pathologically proven meta-
static lymph node was evaluated by level, diameter, and
perinodal extension.
All patients received surgery for the primary site and
neck. Resection of the primary site was grouped by the
extent of the resection as simple excision, hemiglossec-
tomy, and wide excision. None of the patients underwent
a total glossectomy. Neck node dissection was performed
in 64 patients. The Type of neck dissection used was elec-
tive supraomohyoid except 4 cases of modified radical
neck dissection. Fourteen patients received PORT.
Because this was a retrospective study, the indication for
RT had been determined by the individual physician. Fol-
low-up time was calculated from the date of the cancer
operation until the date of the last hospital visit, admis-
sion, or death, and each event-free survival was calcu-
lated from the date of the cancer operation to the date of
diagnosis of each event. The five-year disease-free sur-
vival (DFS) rate, local recurrence-free survival (LRFS)
rate, regional recurrence-free survival (RRFS) rate, dis-
tant metastasis--free survival (DMFS) rate, and overall
survival (OS) rate were calculated using the Kaplan-
Meier method. The differences in survival rates were
compared by the log-rank test. Prognostic factors influ-
encing survival were analyzed by univariate and multivar-
iate analyses using Cox's proportional hazards model. A p
value ≤ 0.05 was considered statistically significant.
Results
Patient and tumor characteristics
Patient characteristics are listed in Table 1. Ages ranged
from 23 to 82 years, with a median of 54 years. All of the
patients showed an Eastern Cooperative Oncology Group
(ECOG) performance status 0 or 1. There were 50 (58%)
patients with stage I, 22 (26%) with stage II, and 14 (16%)
with stage III disease. Pathologic specimens were graded
as well, moderately, or poorly differentiated, according to
the World Health Organization criteria. Fifty-two
patients (61%) had well-differentiated disease, and 34
(39%) moderate-to-poorly differentiated disease. Among
the total of 86 patients, 14 patients (16%) received PORT.
Of the 14 patients, 10 received neck node RT by bilateral
neck node irradiation. The average dose to the primary
area was 59.7Gy, involved neck area was 57.1Gy, and elec-
tive neck area was 45.6Gy. In case of close or positive
margin, 60-65 Gy was given. Seven patients of 14 patients
(50%) received 3-dimensional conformal therapy or
intensity modulated radiation therapy.
Survival and prognostic analysis
The median follow-up was 45 months (range: 4- 99
months). The five-year OS and DFS rates were 80.8% and
80.2%, respectively (Figure 1). By univariate analysis,
grade of differentiation was determined to be the statisti-
cally significant prognostic factor for five-year DFS,
LRFS, RRFS, DMFS, and OS rates. Invasion depth was a
significant factor predictive of five-year DFS, RRFS, and
OS rates (Table 2). By multivariate analysis regarding the
OS and DFS rates, two factors proven to be significant by
the univariate analysis were confirmed to be statistically
significant (Table 3).
Patterns of failure
The 18 cases of recurrence in total included 8 local fail-
ures, 15 regional failures, and 8 distant metastases. Five
patients showed local and regional failures, 7 showed
regional and distant failures, and one patient showed
local and distant failures. Of those patient with initial
recurrences, salvage treatment was attempt in 15
patients. The operation was performed in 8 patients and
4 patients received PORT only and two patients received
concurrent chemo-radiotherapy (CCRT). Three patients
received CCRT without the operation, two received che-
motherapy only and two received RT only. Of the 18
patients of recurrence cases, 13 died. Of patients who
could undergo an operation by salvage treatment, 4Shim et al. Radiation Oncology 2010, 5:43
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patients were successfully treated by salvage treatment
and followed up as having no evidence of disease but 13
died of the disease and 1 survived with the disease during
the follow-up period. Patients who showed only local fail-
ures did not die, and only those who showed regional fail-
ures or distant metastases died. The 14 patients who
received RT did not show any local failure. However, two
of them showed regional failures and died within six
months after treatments that revealed regional failures
and lung metastases. There were four intercurrent
deaths. One patient died of end stage renal disease, one
died of stomach cancer and remaining patients died of
other chronic diseases.
Risk group analysis
Fifty-seven patients had an invasion depth over 0.5 cm or
a grade of moderate-to-poor, and all the recurrences were
found in this group. These patients were divided into
those who had received RT and those who had not. The
recurrence rates of the two groups were reviewed, and
the results are shown in Table 4. Although there was no
statistically significant difference among the recurrence
rates, there was no local failure in the group that received
RT.
Discussion
This study retrospectively observed the treatment results
o f  p a t i e n t s  w i t h  o r a l  t o n g u e  c a n c e r  i n  r e l a t i v e l y  e a r l y
stages corresponding to T1-2N0-1. Operative treatments
have been primarily performed for early oral tongue can-
cers, and, although there have been some reports that
five-year survival rates of stage I-II diseases were 80% or
higher [9]. Rusthoven et al. reported the five-year survival
and cause-specific survival rates of stage I and II oral
tongue cancers as 60.9% and 83.5%, respectively, and in
other oral cavity subsites as 64.7% and 94.1%, respec-
tively, based on the patient SEER database [10]. Although
the prognosis of oral tongue cancers was poorer than that
of cancers in other oral cavity sites, in this study, the five-
year OS and DFS were shown as 80.8% and 80.2%, respec-
tively, far better than those from other reports. This is
thought to be due to the appropriate RT performed in
this institute against early tongue cancers along with
operative treatments.
Although primary RT and surgery are potential treat-
ment options for oral tongue cancer, most oral tongue
cancers are treated surgically [1]. Currently, RT is often
Table 1: Patient's characteristics (n = 86)
Characteristics No. of cases %
Age (year) < 55 38 44
≥ 55 48 56
Gender Male 48 56
Female 38 44
Performance ECOG 0 23 27
ECOG 1 63 73
T classification T1 55 64
T2 31 36
N classification N0 72 84
N1 14 16
Stage I 50 58
II 22 26
III 14 16
Grade Well 52 61
Moderate-poor 34 39
Invasion depth (cm) ≤ 0.5 48 56
> 0.5 38 44
Resection margin Negative 65 76
Close (< 0.5 cm) 19 22
Positive 2 2
Lymphovascular invasion Yes 3 4
No 83 96
Perineural invasion Yes 3 4
No 83 96
Radiotherapy Yes 14 16
No 72 84
Op of primary site Simple excision 11 13
Hemiglossectomy 66 77
Wide excision 9 11
Neck dissection Yes 64 74
No 22 26
Abbreviations : ECOG = Eastern Cooperative Oncology Group.
Figure 1 Kaplan-Meier plots of overall and disease-free survival. 
Five-year survival rates were 80.8% and 80.2%, respectivelyShim et al. Radiation Oncology 2010, 5:43
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Table 2: Univariate analysis of five-year disease-free survival (DFS), local recurrence-free survival (LRFS), regional 
recurrence-free survival (RRFS), distant metastasis-free survival (DMFS) rate, and overall survival (OS) rate
5-year DFS 5-year LRFS 5-year RRFS 5-year DMFS 5-year OS
(%) p value (%) p value (%) p value (%) p value (%) p value
Age (year) 0.233 0.239 0.712 0.312 0.789
< 55 84 97 84 89 84
≥ 55 77 87 78 93 77
Performance 0.718 0.162 0.44 0.692 0.421
ECOG 0 87 100 87 87 87
ECOG 1 77 88 78 94 78
T classification 0.331 0.575 0.101 0.856 0.186
T1 84 91 85 96 86
T2 74 94 73 83 71
N classification 0.725 0.963 0.52 0.856 0.186
N0 81 92 82 91 83
N1 79 93 79 92 67
Stage 0.568 0.685 0.218 0.228 0.151
I8 5 9 0 8 6 9 6 8 7
II 72 96 72 82 73
III 79 93 79 92 67
Grade 0.005 0.015 0.013 0.024 0.001
Well 88 95 89 96 91
Moderate-poor 69 86 69 84 65
Invasion depth (cm) 0.018 0.166 0.008 0.201 0.023
≤ 0.5 92 98 92 96 92
> 0.5 66 83 66 87 66
Resection margin 0.186 0.624 0.081 0.292 0.360
Negative 84 92 86 94 84
Close (< 0.5 cm) or 
positive
65 89 62 86 67
Lymphovascular 
invasion
0.358 0.686 0.292 0.043 0.586
Yes 67 100 67 67 50
No 81 91 82 93 82
Perineural invasion 0.662 0.135 0.598 0.602 0.283
Yes 67 67 50 100 67
No 81 93 82 91 81
Radiotherapy 0.475 0.161 0.775 0.548 0.647
Yes 86 100 86 86 86
No 79 90 80 93 80
Operation of primary site 0.284 0.608 0.775 0.548 0.647
Simple excision 74 83 74 100 81
Hemiglossectomy 78 82 80 89 81
Wide excision 100 100 100 100 100
Neck dissection 0.534 0.556 0.518 0.898 0.882
Yes 82 93 83 92 81
No 76 88 75 90 80
Abbreviations : ECOG = Eastern Cooperative Oncology GroupShim et al. Radiation Oncology 2010, 5:43
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used in addition to surgery and tends to be given postop-
eratively, often because of unfavorable histology. Many
oncologists would recommend adjuvant RT for large
tumors if surgical margins are close to or involved with
the tumor or after neck dissection where there are many
positive nodes. In this study, RT was performed accord-
ing to the opinions of surgeons, rather than to certain cri-
teria, and, consequently, determining the role of RT was
difficult. The 14 patients who were treated by RT consti-
tuted too small a sample for significant analysis. Thus,
comparison of the results of patients who received RT
with the results of those who did not may not be mean-
ingful. However, no local failure occurred among patients
who had exhibited risk factors and had received RT.
Although this result was not indicated to be statistically
significant because the number of patients was not large
enough, it may become a finding helpful in performing
radiation therapy against early tongue cancers later.
Recently, awareness of the frequency of occult node
metastases in early tongue cancer has increased, and
researchers have attempted to identify molecular markers
predictive of occult node metastases [11]. The lymphatic
system of the oral tongue shows extensive communica-
tion across the midline, so carcinomas of the oral tongue
can metastasize bilaterally. The regional recurrence rate
of the untreated N0 neck was found to be between 30 and
47% for early T1-T2 carcinoma [12], and which has led
many authors to propose elective neck dissection. Many
institutes have reported that improved neck control and
increased survival rates have been achieved by adopting
elective neck dissections [13]. Nodal recurrence in the
contralateral neck is a significant cause of regional failure
after elective ipsilateral neck dissection, and postopera-
tive irradiation is recommended for cases of more than
three positive nodes or in the presence of extra capsular
invasion. Elective neck irradiation is advantageous in that
it can be used as an alternative to neck dissections or to
treat both sides of the neck after a neck dissection. In
many reports, elective whole neck irradiation provided
higher control rates, as compared to patients managed
with limited or no neck treatment [14]. In the current
study, among the 57 patients with risks, regional failures
were observed in 13 patients of 44 (29%) with no neck
irradiation and in 2 patients of 13 (15%) treated with neck
irradiation. Although this result is not statistically signifi-
cant, fewer regional failures occurred in cases where
adjuvant RT was performed in the neck area. Studies to
e l u c i d a t e  t h e  r o l e  o f  R T  i n  r e l a t i o n  t o  r e g i o n a l  r e c u r -
rences, as well as local recurrences, should be continued.
Risk factors for recurrence in oral tongue cancer
include an infiltrating pattern of tumor growth, diffuse
histological invasion, and a tumor within 5 mm of the
resection margin [15]. This study has retrospectively ana-
lyzed prognostic factors for patients with T1-2N0-1 OSCC
treated primarily by surgery in an attempt to define more
exactly a subgroup at high risk for recurrence. A number
Table 4: Disease recurrence in the risk group according to radiation therapy
Radiation therapy (n = 13) No radiation therapy (n = 44) p value
No. of patients % No. of patients %
Local recurrence 0 0 8 18 0.107
Regional 
recurrence
21 5 1 3 2 9 0 . 2 5 2
Distant 
recurrence
21 561 4 0 . 5 9 1
Total recurrence 2 15 16 36 0.137
Table 3: Multivariate analysis of overall survival and disease-free survival rate
Overall survival rate Disease-free survival rate
HR (95% CI) p value HR (95% CI) p value
Grade (well vs. mod-poor) 6.93 (2.23-21.56) 0.001 4.16 (1.55-11.18) 0.005
Invasion depth (≤ 0.5 vs. > 0.5) 3.94 (1.39-11.14) 0.01 3.51 (1.31-9.46) 0.013
Abbreviations: HR = hazard ratio; CI = confidence interval.Shim et al. Radiation Oncology 2010, 5:43
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of histo-pathological parameters were evaluated to iden-
tify patients at high-risk for locoregional control and sur-
vival, including tumor grade, depth of invasion, tumor
size, and the status of the resection margin. In this study,
depth of invasion and tumor grade seemed to affect the
DFS and OS rates. Al-Rajhi et al. reported that tumor
thicknesses affected prognoses, and that lesions less than
10 mm had remarkably favorable prognoses [16]. How-
ever, the critical tumor thickness limit varied from 2 to 10
mm in different studies [15]. There is no agreement on
the appropriate tumor thickness below which elective
treatment should not be recommended. With regard to
tumor grade, Arduino et al. reported that histological
grading was related, as an independent factor, in predict-
i n g  s u rv i v a l  i n  p a t i e n t s  w i t h  o r a l  s q u a m o u s  c e l l  c a r c i -
noma [17]. In this study, tumor grades were shown to be
factors related to OS and DSF rates. Therefore, aggressive
treatments should be considered for patients with these
risk factors.
Although the combination of chemotherapy with sur-
gery and RT has improved cure rates in some other head
and neck cancers, its role in the management of oral cav-
ity tumors is not clear. Some advocate its use in young
patients, when there are multiple involved cervical nodes,
and in the presence of adverse histological features [5].
Although no survival benefit has been confirmed to date,
the results of studies involving large series are awaited.
The past decade has seen the advent of intensity-modu-
lated radiotherapy (IMRT) to treat head and neck cancer.
Toxicity and locoregional control rates have been promis-
ing [18,19]. Gomez et al. advocate using IMRT when
available for all patients treated in the postoperative set-
ting for oral cavity, because acceptable acute toxicity of
normal structures has been found with at least similar (if
not superior) outcomes for local control [20]. In this
study, of 14 patients who received RT, three received
IMRT. Although it was difficult to analyze toxicity due to
the limitation of the retrospective study, the patients who
received IMRT showed tolerable toxicity. Radiation to the
oral cavity can develop complications and affect patients'
quality of life. Further studies with larger numbers of
patients are necessary and should include the follow-up
data of complications in addition to the disease status and
survival.
There are several limitations in this study because it is
retrospective. The number of patients was small enough
that further analysis may yield additional possible adverse
prognostic factors, such as ECS and PNI, which were not
statistically significant in this study. Also difficult is to
evaluate the importance of PORT in early oral tongue
cancer because of the small number of irradiated
patients. However, this study has summarized results of
therapy targeting T1-2N0-1 OSCC in order to elucidate
prognostic factors and improve postoperative clinical
applications of RT.
Conclusion
In T1-2N0-1 OSCC, factors that significantly associated
with prognosis after primary surgery were poor tumor
differentiation and deep invasion depths over 0.5 cm.
PORT was not significantly related to clinical outcomes
in T1-2N0-1 OSCC. Although not statistically significant,
notably, no local failure occurred in the patients who
received PORT in the high-risk group. PORT should
therefore, be considered in early oral tongue cancer
patients with high-risk pathologic features.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SJS and KCK developed the ideas for these experiments, performed much of
the work, and drafted the manuscript. JC, WSK, GEK, CGL, and ECC designed
the study, collected the data and interpreted the data. SJS and JC performed
the statistical analysis. All authors read and approved the final manuscript.
Author Details
1Department of Radiation Oncology, Eulji Hospital, Eulji Medical Center, Seoul, 
Korea, 2Department of Radiation Oncology, Yonsei Cancer Center, Yonsei 
University Health System, Seoul, Korea and 3Department of 
Otorhinolaryngology, Yonsei Cancer Center, Yonsei University Health System, 
Seoul, Korea
References
1. Chen AY, Myers JN: Cancer of the oral cavity.  Dis Mon 2001, 47:275-361.
2. Fein DA, Mendenhall WM, Parsons JT, McCarty PJ, Stringer SP, Million RR, 
Cassisi NJ: Carcinoma of the oral tongue: a comparison of results and 
complications of treatment with radiotherapy and/or surgery.  Head 
Neck 1994, 16:358-365.
3. Robertson AG, Soutar DS, Paul J, Webster M, Leonard AG, Moore KP, 
McManners J, Yosef HM, Canney P, Errington RD, et al.: Early closure of a 
randomized trial: surgery and postoperative radiotherapy versus 
radiotherapy in the management of intra-oral tumours.  Clin Oncol (R 
Coll Radiol) 1998, 10:155-160.
4. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, 
Giralt J, Maingon P, Rolland F, Bolla M, et al.: Postoperative irradiation 
with or without concomitant chemotherapy for locally advanced head 
and neck cancer.  N Engl J Med 2004, 350:1945-1952.
5. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish 
JA, Kim HE, Cmelak AJ, Rotman M, et al.: Postoperative concurrent 
radiotherapy and chemotherapy for high-risk squamous-cell 
carcinoma of the head and neck.  N Engl J Med 2004, 350:1937-1944.
6. Lefebvre JL, Coche-Dequeant B, Buisset E, Mirabel X, Van JT, Prevost B: 
Management of early oral cavity cancer. Experience of Centre Oscar 
Lambret.  Eur J Cancer B Oral Oncol 1994, 30B:216-220.
7. Lapeyre M, Bollet MA, Racadot S, Geoffrois L, Kaminsky MC, Hoffstetter S, 
Dolivet G, Toussaint B, Luporsi E, Peiffert D: Postoperative brachytherapy 
alone and combined postoperative radiotherapy and brachytherapy 
boost for squamous cell carcinoma of the oral cavity, with positive or 
close margins.  Head Neck 2004, 26:216-223.
8. Yuen AP, Wei WI, Wong YM, Tang KC: Elective neck dissection versus 
observation in the treatment of early oral tongue carcinoma.  Head 
Neck 1997, 19:583-588.
9. Soutar DS, McGregor IA: The radial forearm flap in intraoral 
reconstruction: the experience of 60 consecutive cases.  Plast Reconstr 
Surg 1986, 78:1-8.
Received: 23 March 2010 Accepted: 27 May 2010 
Published: 27 May 2010
This article is available from: http://www.ro-journal.com/content/5/1/43 © 2010 Shim et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Radiation Oncology 2010, 5:43Shim et al. Radiation Oncology 2010, 5:43
http://www.ro-journal.com/content/5/1/43
Page 7 of 7
10. Rusthoven K, Ballonoff A, Raben D, Chen C: Poor prognosis in patients 
with stage I and II oral tongue squamous cell carcinoma.  Cancer 2008, 
112:345-351.
11. Keum KC, Chung EJ, Koom WS, Cho JH, Cho SH, Choi EC, Lee CG, Suh CO, 
Kim GE: Predictive value of p53 and PCNA expression for occult neck 
metastases in patients with clinically node-negative oral tongue 
cancer.  Otolaryngol Head Neck Surg 2006, 135:858-864.
12. Kligerman J, Lima RA, Soares JR, Prado L, Dias FL, Freitas EQ, Olivatto LO: 
Supraomohyoid neck dissection in the treatment of T1/T2 squamous 
cell carcinoma of oral cavity.  Am J Surg 1994, 168:391-394.
13. Fakih AR, Rao RS, Borges AM, Patel AR: Elective versus therapeutic neck 
dissection in early carcinoma of the oral tongue.  Am J Surg 1989, 
158:309-313.
14. Spaulding CA, Korb LJ, Constable WC, Cantrell RW, Levine PA: The 
influence of extent of neck treatment upon control of cervical 
lymphadenopathy in cancers of the oral tongue.  Int J Radiat Oncol Biol 
Phys 1991, 21:577-581.
15. Kirita T, Okabe S, Izumo T, Sugimura M: Risk factors for the postoperative 
local recurrence of tongue carcinoma.  J Oral Maxillofac Surg 1994, 
52:149-154.
16. Al-Rajhi N, Khafaga Y, El-Husseiny J, Saleem M, Mourad W, Al-Otieschan A, 
Al-Amro A: Early stage carcinoma of oral tongue: prognostic factors for 
local control and survival.  Oral Oncol 2000, 36:508-514.
17. Arduino PG, Carrozzo M, Chiecchio A, Broccoletti R, Tirone F, Borra E, 
Bertolusso G, Gandolfo S: Clinical and histopathologic independent 
prognostic factors in oral squamous cell carcinoma: a retrospective 
study of 334 cases.  J Oral Maxillofac Surg 2008, 66:1570-1579.
18. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM: Intensity-
modulated radiation therapy for head-and-neck cancer: the UCSF 
experience focusing on target volume delineation.  Int J Radiat Oncol 
Biol Phys 2003, 57:49-60.
19. Hoppe BS, Wolden SL, Zelefsky MJ, Mechalakos JG, Shah JP, Kraus DH, Lee 
N: Postoperative intensity-modulated radiation therapy for cancers of 
the paranasal sinuses, nasal cavity, and lacrimal glands: technique, 
early outcomes, and toxicity.  Head Neck 2008, 30:925-932.
20. Gomez DR, Zhung JE, Gomez J, Chan K, Wu AJ, Wolden SL, Pfister DG, 
Shaha A, Shah JP, Kraus DH, et al.: Intensity-modulated radiotherapy in 
postoperative treatment of oral cavity cancers.  Int J Radiat Oncol Biol 
Phys 2009, 73:1096-1103.
doi: 10.1186/1748-717X-5-43
Cite this article as: Shim et al., Clinical outcomes for T1-2N0-1 oral tongue 
cancer patients underwent surgery with and without postoperative radio-
therapy Radiation Oncology 2010, 5:43